Physician profile
Mark F Dollar
NPI 1508824970
$6,213.29
in general payments reported to CMS, 2019-2025
34 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $692 · 2021: $1,281 · 2022: $1,194 · 2023: $1,173 · 2024: $990 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,273.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $846.63 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $608.57 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $427.10 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.81 | 2020-2025 | Jardiance, Ofev, Tradjenta |
| Glaxosmithkline, LLC. | $355.46 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $327.93 | 2022-2025 | |
| Lilly USA, LLC | $251.56 | 2020-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $179.16 | 2021-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $157.29 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $148.35 | 2021-2023 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.89 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $139.59 | 2021-2022 | |
| Abbott Laboratories | $114.16 | 2023-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $110.01 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $92.23 | 2019-2023 | Seglentis, Livalo |
| Esperion Therapeutics, INC. | $84.54 | 2021 | |
| Antares Pharma, INC. | $78.99 | 2020-2024 | Xyosted |
| Merck Sharp & Dohme LLC | $58.74 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Biohaven Pharmaceutical Holding Company Ltd. | $51.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $49.96 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $45.55 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $43.47 | 2020 | |
| Ironwood Pharmaceuticals, INC | $34.56 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.91 | 2024-2025 | Caplyta |
| Genentech USA, INC. | $32.67 | 2019-2021 | |
| Astellas Pharma US INC | $29.23 | 2022-2023 | Veozah |
| Eisai INC. | $25.20 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.47 | 2025 | Qelbree, Tlando, Xyosted |
| Xeris Pharmaceuticals, INC. | $19.05 | 2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $15.57 | 2023 | Auvelity |
| Boston Scientific Corporation | $14.92 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.14 | 2022 | |
| Halozyme INC | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.